Codagene Spółka z Ograniczoną Odpowiedzialnością (KRS 0000615808, NIP 9492207325) is a Polish company, headquartered in Częstochowa, Śląskie voivodeship. Codagene operates in: Research and experimental development on biotechnology (PKD 72.11.Z). Industry: Research and development. The company has been listed in the National Court Register since April 28, 2016.
No arrears identified in the analysed sources
No arrears or bankruptcy proceedings identified in the analysed sources.
Business profile - Codagene
Identity
- Name
- Codagene Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- April 28, 2016
- Registry status as of
- November 21, 2025
- Latest entry
- March 31, 2025
- Founding act
- 27.04.2016 R.
Articles of association history (3)
- April 27, 2016: 27.04.2016 R.
- November 29, 2016: 29.11.2016 R., NOTARIUSZ MICHAŁ PILARZ, KANCELARIA NOTARIALNA W CZĘSTOCHOWIE UL. DĄBROWSKIEGO 8 LOK. 5, REPERTORIUM A NUMER 1613/2016 - ZMIANA: § 3, § 4
- March 24, 2021: 24.03.2021 R. W KN JOANNY JASTRZĄB-STANDERSKIEJ W CZĘSTOCHOWIE, REP. A NR 2332/2021 ZMIENIONO § 3
Activities
Other activities
Address and contact
- Address
- UL. LWOWSKA, 43A, 42-200, CZĘSTOCHOWA, POLSKA
- Voivodeship
- ŚLĄSKIE
- District
- CZĘSTOCHOWA
- INFO@CODAGENE.COM
- Website
- CODAGENE.COM
- E-delivery address
- Not disclosed in the registry
- Coordinates
- 50.8052, 19.1183approx.
Operational status - Codagene
Founded
April 28, 2016
10 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
CZĘSTOCHOWA
ŚLĄSKIE
Primary PKD
72.11.Z
Research and experimental development on biotechnology
Share capital
5.0 K PLN
95 shares total
Shareholders
1
shareholder
Board
1 person
Filed years
N/A
Registry entries
32
latest: March 31, 2025
No KPI data - financial statements and valuation are unavailable for this company.
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - Codagene.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase on BCX-CM-J – potentially Europe's first veterinary cell-therapy drug based on mesenchymal stem cells, for dogs with osteoarthritis. Responses to the EMA's final questions are due in May 2026; a CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. A pre-commercial biotech: it closed 2024 with a PLN 14.9m loss on zero revenue and PLN 33.6m of cash at year-end. Trigon DM maintains a buy rating with a PLN 127.2 price target.
News
Captor Therapeutics: PLN 36m of cash at 30 September 2025, runway to mid-2026 – clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) – a pre-commercial biotech specialising in targeted protein degradation (TPD) – closed Q3 2025 with PLN 36m of cash and grants securing funding to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I, with the first patient dosed at the Barcelona Clinic Liver Cancer. CT-03, an MCL-1 degrader, is close to clinical entry. Without a new R&D partnership or share issue in 2026, the company will need additional financing.
